Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02038829 · ClinicalTrials.gov registry record · Phase 2
A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD
A Phase 2 study, sponsored by Sunovion Respiratory Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT02038829 is a Phase 2 study that has completed, run by Sunovion Respiratory Development. The registered enrollment target is 96 participants.
The verdict
NCT02038829, a Phase 2 study, has completed, sponsored by Sunovion Respiratory Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.
Interventions
- DRUG Placebo
- DRUG SUN101 3 mcg
- DRUG SUN-101 6.25 mcg
- DRUG SUN-101 12.5 mcg
- DRUG SUN-101 50 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02038829
The ClinicalTrials.gov registry entry for NCT02038829 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunovion Respiratory Development, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02038829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02038829 about?
NCT02038829 is a clinical study titled "A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD". Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.
What is the current status of trial NCT02038829?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2014-01. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02038829?
The interventions under investigation include: Placebo (DRUG), SUN101 3 mcg (DRUG), SUN-101 6.25 mcg (DRUG), SUN-101 12.5 mcg (DRUG), SUN-101 50 mcg (DRUG).
Who is sponsoring clinical trial NCT02038829?
This trial is sponsored by Sunovion Respiratory Development, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.